Trial reportDrug design, development and therapy2026
Effects of Different Timing of Administration of Azasetron on the Prevention of Postoperative Nausea and Vomiting After Gynecological Laparoscopic Surgery: A Single Center, Double-Blind Randomized Controlled Trial.
Trial report in Drug design, development and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Postoperative nausea and vomiting (PONV) is a common complication in gynecological laparoscopic surgery. Azasetron is a commonly used injectable antiemetic for PONV prevention in clinical practice. However, the impact of its administration method, particularly the timing of administration, on PONV remains ambiguous. The objective of this study was to evaluate the impact of various administration regimens of azasetron on its antiemetic efficacy in patients undergoing laparoscopic gynecological surgery. Methods: In this prospective study, 129 elective laparoscopic gynecological surgery patients were randomized 1:1:1 to three groups. Group A received azasetron 10 mg intravenously before anesthesia induction. Group B received azasetron 5 mg intravenously before induction and an additional 5 mg before the end of surgery. Group C received azasetron 10 mg intravenously before the end of surgery. The primary outcome was 24-hour PONV incidence. Secondary outcomes included PONV severity (0-2 and 2-24 hours), rescue antiemetic use within 24 hours, PACU and hospital stay lengths, and adverse events. Results: There were no significant differences in the incidence and severity of PONV among Groups A, B, and C during the 24-hour follow-up period. The incidence of PONV 24 hours following surgery were 30.2%, 37.2%, and 30.2% (P = 0.728) in Groups A, B, and C, respectively. The incidence of postoperative adverse events was equivalent in both three groups. Group B demonstrated the highest demand for rescue antiemetic medications (P = 0.021), and the length of stay in the Post-Anesthesia Care Unit (PACU) was significantly extended (P = 0.012). Conclusion: No significant difference was observed in PONV prevention within 24 hours postoperatively when comparing intravenous administration of 10 mg azasetron before anesthesia induction versus before surgical conclusion in gynecological laparoscopic surgery. In the context of 10 mg dosage of azasetron, the split-dose regimen increases the 24-hour rescue antiemetic requirements.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.